The group's subsidiaries -- HLB Life Science and HLB Pharmaceutical -- and CG Invites (formerly Crystal Genomics) have inked an agreement to collaborate on the domestic approval process and sales and marketing activities for the riboceranib+camrelizumab combo therapy.
 

Please refer to the following website for further details : HLB Pharmaceutical secures domestic rights to riboceranib+camrelizumab combo